{"id": "article-132588_0", "title": "Difelikefalin -- Continuing Education Activity", "content": "Difelikefalin is a medication used to treat and manage uremic pruritis and postoperative pain, affecting patients' quality of life. Difelikefalin is in the opioid class of drugs and works as a selective kappa-opioid receptor agonist; alternative names for difelikefalin include 4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)piperidine-4-carboxylic acid, CKD-943, MR13A9, FE202845, and CR 845. Since difelikefalin is peripherally selective, it is unlikely to cause lethal central nervous system\u00a0adverse effects such as respiratory depression. IV dosing schedule after dialysis sessions enhances treatment logistics and patient outcomes. Moreover, difelikefalin presents as a safer alternative for managing postoperative pain amid the opioid crisis, offering decreased abuse potential and promising results in early trials. However, further research is needed to validate its efficacy and safety, especially in patients with diabetes and end-stage renal disease. This activity describes the mechanism of action, indications, administration, adverse effects, monitoring, and contraindications for difelikefalin therapy pertinent for interprofessional team members in treating patients\u00a0with uremic pruritis or postoperative pain.", "contents": "Difelikefalin -- Continuing Education Activity. Difelikefalin is a medication used to treat and manage uremic pruritis and postoperative pain, affecting patients' quality of life. Difelikefalin is in the opioid class of drugs and works as a selective kappa-opioid receptor agonist; alternative names for difelikefalin include 4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)piperidine-4-carboxylic acid, CKD-943, MR13A9, FE202845, and CR 845. Since difelikefalin is peripherally selective, it is unlikely to cause lethal central nervous system\u00a0adverse effects such as respiratory depression. IV dosing schedule after dialysis sessions enhances treatment logistics and patient outcomes. Moreover, difelikefalin presents as a safer alternative for managing postoperative pain amid the opioid crisis, offering decreased abuse potential and promising results in early trials. However, further research is needed to validate its efficacy and safety, especially in patients with diabetes and end-stage renal disease. This activity describes the mechanism of action, indications, administration, adverse effects, monitoring, and contraindications for difelikefalin therapy pertinent for interprofessional team members in treating patients\u00a0with uremic pruritis or postoperative pain."}
{"id": "article-132588_1", "title": "Difelikefalin -- Continuing Education Activity", "content": "Objectives: Identify patients with uremic pruritus and post-operative pain who may benefit from difelikefalin therapy. Screen patients for contraindications, potential drug interactions, and other factors that may impact the safe and effective use of difelikefalin. Assess the effectiveness of difelikefalin therapy in managing uremic pruritus and postoperative pain, monitoring treatment response, and adjusting the treatment plan as needed. Collaborate with other healthcare professionals, such as nephrologists, anesthesiologists, and pain management specialists, to ensure coordinated care and optimize the use of difelikefalin in managing uremic pruritus and post-operative pain. Access free multiple choice questions on this topic.", "contents": "Difelikefalin -- Continuing Education Activity. Objectives: Identify patients with uremic pruritus and post-operative pain who may benefit from difelikefalin therapy. Screen patients for contraindications, potential drug interactions, and other factors that may impact the safe and effective use of difelikefalin. Assess the effectiveness of difelikefalin therapy in managing uremic pruritus and postoperative pain, monitoring treatment response, and adjusting the treatment plan as needed. Collaborate with other healthcare professionals, such as nephrologists, anesthesiologists, and pain management specialists, to ensure coordinated care and optimize the use of difelikefalin in managing uremic pruritus and post-operative pain. Access free multiple choice questions on this topic."}
{"id": "article-132588_2", "title": "Difelikefalin -- Indications", "content": "The use of opioid medication for analgesia dates back to the 1800s. One of the original opioid medications, morphine, named after Morpheus, the god of dreams, was extracted from opium plants and injected intravenously (IV) to provide analgesia in patients suffering from neuralgia. In the 1990s, various extended-release oral opioid formulations were introduced to the market.", "contents": "Difelikefalin -- Indications. The use of opioid medication for analgesia dates back to the 1800s. One of the original opioid medications, morphine, named after Morpheus, the god of dreams, was extracted from opium plants and injected intravenously (IV) to provide analgesia in patients suffering from neuralgia. In the 1990s, various extended-release oral opioid formulations were introduced to the market."}
{"id": "article-132588_3", "title": "Difelikefalin -- Indications", "content": "These oral formulations made available in high doses marked the beginning of the opioid crisis in the United States today. When\u00a0combined with tolerance and lethal central nervous system (CNS) adverse effects, the euphoric effects of these medications pose a dangerous situation for patients seeking pain relief. The opioid crisis has made the transition to illegal drug use and death by overdose, with oral formulations, commonplace. In the United States, in 2016, over 230 million opioid prescriptions were written to treat acute and chronic pain. The\u00a0survey showed that\u00a01 in every\u00a03 Americans had been prescribed an opioid medication. Safe and effective pain management remains challenging for the clinician\u00a0and interprofessional healthcare team. The market for novel opioid medications with less abuse potential and fewer dangerous\u00a0adverse effects is vast. [1] [2]", "contents": "Difelikefalin -- Indications. These oral formulations made available in high doses marked the beginning of the opioid crisis in the United States today. When\u00a0combined with tolerance and lethal central nervous system (CNS) adverse effects, the euphoric effects of these medications pose a dangerous situation for patients seeking pain relief. The opioid crisis has made the transition to illegal drug use and death by overdose, with oral formulations, commonplace. In the United States, in 2016, over 230 million opioid prescriptions were written to treat acute and chronic pain. The\u00a0survey showed that\u00a01 in every\u00a03 Americans had been prescribed an opioid medication. Safe and effective pain management remains challenging for the clinician\u00a0and interprofessional healthcare team. The market for novel opioid medications with less abuse potential and fewer dangerous\u00a0adverse effects is vast. [1] [2]"}
{"id": "article-132588_4", "title": "Difelikefalin -- Indications", "content": "Kappa, delta, and mu-opioid receptors are present in various human tissues and can be targeted in treating acute and chronic pain. Opioid receptor distribution in patients with end-stage renal disease requiring hemodialysis plays a role in the chronic itch that they can experience. [3] Polypharmacy is commonly involved in managing these patients, who often have many comorbidities and decreased quality of life. The potential for selective opioid medications to target specific receptors in peripheral tissues is groundbreaking, and it offers the opportunity to treat the etiology of itch that patients with end-stage renal disease may suffer from.", "contents": "Difelikefalin -- Indications. Kappa, delta, and mu-opioid receptors are present in various human tissues and can be targeted in treating acute and chronic pain. Opioid receptor distribution in patients with end-stage renal disease requiring hemodialysis plays a role in the chronic itch that they can experience. [3] Polypharmacy is commonly involved in managing these patients, who often have many comorbidities and decreased quality of life. The potential for selective opioid medications to target specific receptors in peripheral tissues is groundbreaking, and it offers the opportunity to treat the etiology of itch that patients with end-stage renal disease may suffer from."}
{"id": "article-132588_5", "title": "Difelikefalin -- Indications", "content": "Difelikefalin\u00a0is indicated\u00a0for treating moderate-to-severe pruritus associated with chronic kidney disease in\u00a0adults undergoing hemodialysis\u00a0and is FDA-approved for that purpose. [1] [4] [5] In phase\u00a03 clinical trials,\u00a0IV difelikefalin\u00a0showed analgesic efficacy in treating post-operative pain and uremic pruritus in patients with end-stage renal disease who require hemodialysis. [5] [6] [1] Phase\u00a02 clinical trials\u00a0examining off-label utilization of difelikefalin for notalgia paresthetica and paroxysmal neuropathic pruritus in pediatric\u00a0patients with Type I Chiari\u00a0malformations suggest the utility of the kappa opioid receptor\u00a0for pruritis of neuropathic etiology. [7] [8]", "contents": "Difelikefalin -- Indications. Difelikefalin\u00a0is indicated\u00a0for treating moderate-to-severe pruritus associated with chronic kidney disease in\u00a0adults undergoing hemodialysis\u00a0and is FDA-approved for that purpose. [1] [4] [5] In phase\u00a03 clinical trials,\u00a0IV difelikefalin\u00a0showed analgesic efficacy in treating post-operative pain and uremic pruritus in patients with end-stage renal disease who require hemodialysis. [5] [6] [1] Phase\u00a02 clinical trials\u00a0examining off-label utilization of difelikefalin for notalgia paresthetica and paroxysmal neuropathic pruritus in pediatric\u00a0patients with Type I Chiari\u00a0malformations suggest the utility of the kappa opioid receptor\u00a0for pruritis of neuropathic etiology. [7] [8]"}
{"id": "article-132588_6", "title": "Difelikefalin -- Mechanism of Action", "content": "Difelikefalin is a selective kappa-opioid receptor agonist. Alternative names for difelikefalin include 4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)piperidine-4-carboxylic acid,\u00a0 KORSUVA, CKD-943, MR13A9, FE202845, and CR 845. [4] [9] Difelikefalin is peripherally selective due to its small hydrophilic peptide structure.\u00a0This drug is not able to cross the blood-brain barrier. Therefore, unlike\u00a0many other opioid medications, it does not cause\u00a0lethal\u00a0CNS adverse effects such as respiratory depression. [10]", "contents": "Difelikefalin -- Mechanism of Action. Difelikefalin is a selective kappa-opioid receptor agonist. Alternative names for difelikefalin include 4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)piperidine-4-carboxylic acid,\u00a0 KORSUVA, CKD-943, MR13A9, FE202845, and CR 845. [4] [9] Difelikefalin is peripherally selective due to its small hydrophilic peptide structure.\u00a0This drug is not able to cross the blood-brain barrier. Therefore, unlike\u00a0many other opioid medications, it does not cause\u00a0lethal\u00a0CNS adverse effects such as respiratory depression. [10]"}
{"id": "article-132588_7", "title": "Difelikefalin -- Mechanism of Action", "content": "Difelikefalin has no action at the mu-opioid receptor, which is responsible for the euphoric effects of traditional opioid medications. Without activity at the mu-opioid receptors in the CNS, negligible abuse potential is apparent for this novel agent. [9] This medication\u00a0selectively acts on kappa opioid receptors in peripheral tissues, contributing to pruritis and nociception. Activating opioid receptors in peripheral neurons and keratinocytes reduces afferent (sensory) impulses toward the CNS, decreasing pain signals. Activating kappa\u00a0opioid\u00a0receptors on immune cells, including monocytes and T lymphocytes, decreases the release of pro-inflammatory chemicals such as prostaglandins. [11] [12] [13]", "contents": "Difelikefalin -- Mechanism of Action. Difelikefalin has no action at the mu-opioid receptor, which is responsible for the euphoric effects of traditional opioid medications. Without activity at the mu-opioid receptors in the CNS, negligible abuse potential is apparent for this novel agent. [9] This medication\u00a0selectively acts on kappa opioid receptors in peripheral tissues, contributing to pruritis and nociception. Activating opioid receptors in peripheral neurons and keratinocytes reduces afferent (sensory) impulses toward the CNS, decreasing pain signals. Activating kappa\u00a0opioid\u00a0receptors on immune cells, including monocytes and T lymphocytes, decreases the release of pro-inflammatory chemicals such as prostaglandins. [11] [12] [13]"}
{"id": "article-132588_8", "title": "Difelikefalin -- Administration", "content": "Difelikefalin can be administered via the oral or IV route. IV dosing is weight-based. [11] [10] IV dosings and administration for uremic pruritus: 0.5 mcg per kg IV bolus into the venous port of the dialysis circuit immediately following dialysis. Weight-based dosing in the treatment of uremic pruritus should be taken into careful consideration when rendering this medication. The appropriate weight-based dose is determined by the clinician and is based on the prescription dry body weight of the patient with end-stage renal disease, where the patient is considered normovolemic. [11] [14] [11]", "contents": "Difelikefalin -- Administration. Difelikefalin can be administered via the oral or IV route. IV dosing is weight-based. [11] [10] IV dosings and administration for uremic pruritus: 0.5 mcg per kg IV bolus into the venous port of the dialysis circuit immediately following dialysis. Weight-based dosing in the treatment of uremic pruritus should be taken into careful consideration when rendering this medication. The appropriate weight-based dose is determined by the clinician and is based on the prescription dry body weight of the patient with end-stage renal disease, where the patient is considered normovolemic. [11] [14] [11]"}
{"id": "article-132588_9", "title": "Difelikefalin -- Administration -- Pharmacokinetics", "content": "Difelikefalin\u00a0showed a dose-proportional response over a single dosage range from 1 to 3 mcg/kg and multiple\u00a0IV dosage range from 0.5 to 2.5 mcg/kg in chronic kidney disease patients undergoing hemodialysis. A steady-state plasma concentration was reached after the second administered dosage, and the mean accumulation ratio was up to 1.6. Bioavailability: 100% Distribution: The mean volume of distribution is approximately 238 mL/kg, and human plasma protein binding in dialysis patients is 23% to 28%. [15] Metabolism: Not metabolized by cytochrome P450 (CYP) enzymes presents in human hepatic microsomes CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP2D6 or CYP3A or in in-vitro hepatocytes; excreted unchanged in urine and bile. Elimination half-life: 2 hours Duration of action: 12 hours after a single IV dose [9]", "contents": "Difelikefalin -- Administration -- Pharmacokinetics. Difelikefalin\u00a0showed a dose-proportional response over a single dosage range from 1 to 3 mcg/kg and multiple\u00a0IV dosage range from 0.5 to 2.5 mcg/kg in chronic kidney disease patients undergoing hemodialysis. A steady-state plasma concentration was reached after the second administered dosage, and the mean accumulation ratio was up to 1.6. Bioavailability: 100% Distribution: The mean volume of distribution is approximately 238 mL/kg, and human plasma protein binding in dialysis patients is 23% to 28%. [15] Metabolism: Not metabolized by cytochrome P450 (CYP) enzymes presents in human hepatic microsomes CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP2D6 or CYP3A or in in-vitro hepatocytes; excreted unchanged in urine and bile. Elimination half-life: 2 hours Duration of action: 12 hours after a single IV dose [9]"}
{"id": "article-132588_10", "title": "Difelikefalin -- Administration -- Specific Patients Population", "content": "Hepatic impairment: No dose adjustment is\u00a0necessary for patients with mild-to-moderate hepatic impairment. However, the impact of the pharmacokinetics of difelikefalin has\u00a0not been evaluated in patients with severe hepatic impairment; therefore, the use of difelikefalin is not recommended in this patient population.", "contents": "Difelikefalin -- Administration -- Specific Patients Population. Hepatic impairment: No dose adjustment is\u00a0necessary for patients with mild-to-moderate hepatic impairment. However, the impact of the pharmacokinetics of difelikefalin has\u00a0not been evaluated in patients with severe hepatic impairment; therefore, the use of difelikefalin is not recommended in this patient population."}
{"id": "article-132588_11", "title": "Difelikefalin -- Administration -- Specific Patients Population", "content": "Renal impairment: The manufacturer label provides no dose adjustment data for patients with\u00a0renal impairment.\u00a0Difelikefalin has not been studied in patients on peritoneal dialysis and\u00a0has no recommendations for use in this patient population.", "contents": "Difelikefalin -- Administration -- Specific Patients Population. Renal impairment: The manufacturer label provides no dose adjustment data for patients with\u00a0renal impairment.\u00a0Difelikefalin has not been studied in patients on peritoneal dialysis and\u00a0has no recommendations for use in this patient population."}
{"id": "article-132588_12", "title": "Difelikefalin -- Administration -- Specific Patients Population", "content": "Pregnant women: Difelikefalin\u00a0is considered a pregnancy category\u00a0B medicine. Limited data on the use of difelikefalin in pregnant women is insufficient to assess a drug-associated risk for significant congenital disabilities or miscarriage. Breastfeeding women: The manufacturer labels do not provide data\u00a0regarding the presence of difelikefalin in human milk, its effects on the breastfed infant, and/or milk production. Pediatric patients: The safety and efficacy of\u00a0difelikefalin\u00a0are not established in pediatric patients.", "contents": "Difelikefalin -- Administration -- Specific Patients Population. Pregnant women: Difelikefalin\u00a0is considered a pregnancy category\u00a0B medicine. Limited data on the use of difelikefalin in pregnant women is insufficient to assess a drug-associated risk for significant congenital disabilities or miscarriage. Breastfeeding women: The manufacturer labels do not provide data\u00a0regarding the presence of difelikefalin in human milk, its effects on the breastfed infant, and/or milk production. Pediatric patients: The safety and efficacy of\u00a0difelikefalin\u00a0are not established in pediatric patients."}
{"id": "article-132588_13", "title": "Difelikefalin -- Administration -- Specific Patients Population", "content": "Older patients: The safety and efficacy of\u00a0difelikefalin\u00a0were\u00a0studied on\u00a0848 subjects in the placebo-controlled trial. [16] In this study,\u00a0278 subjects (32.8%) and 98 subjects (11.6%) were 65 and 75 years of age or older, respectively. No\u00a0overall differences in the safety or\u00a0efficacy of difelikefalin have been observed between\u00a0older and adult patient populations. The incidence of somnolence was 7% higher in\u00a0older\u00a0patients than in adult patients.\u00a0No difference in plasma concentrations of\u00a0difelikefalin has been observed between older and adult patient populations.", "contents": "Difelikefalin -- Administration -- Specific Patients Population. Older patients: The safety and efficacy of\u00a0difelikefalin\u00a0were\u00a0studied on\u00a0848 subjects in the placebo-controlled trial. [16] In this study,\u00a0278 subjects (32.8%) and 98 subjects (11.6%) were 65 and 75 years of age or older, respectively. No\u00a0overall differences in the safety or\u00a0efficacy of difelikefalin have been observed between\u00a0older and adult patient populations. The incidence of somnolence was 7% higher in\u00a0older\u00a0patients than in adult patients.\u00a0No difference in plasma concentrations of\u00a0difelikefalin has been observed between older and adult patient populations."}
{"id": "article-132588_14", "title": "Difelikefalin -- Adverse Effects", "content": "Phase\u00a03 clinical trials involving patients with end-stage renal disease requiring dialysis suffering from uremic pruritus\u00a0involved a study design. Patients received\u00a0IV difelikefalin at weight-based doses of 1.0 mcg per kg\u00a03 times a week in the venous circuit of their dialysis machine for\u00a012 weeks. [5] This study demonstrated\u00a0the following most common adverse effects: Diarrhea Vomiting Dizziness", "contents": "Difelikefalin -- Adverse Effects. Phase\u00a03 clinical trials involving patients with end-stage renal disease requiring dialysis suffering from uremic pruritus\u00a0involved a study design. Patients received\u00a0IV difelikefalin at weight-based doses of 1.0 mcg per kg\u00a03 times a week in the venous circuit of their dialysis machine for\u00a012 weeks. [5] This study demonstrated\u00a0the following most common adverse effects: Diarrhea Vomiting Dizziness"}
{"id": "article-132588_15", "title": "Difelikefalin -- Adverse Effects", "content": "A double-blind, randomized study assessed the potential of difelikefalin to cause respiratory depression in healthy patients compared to a placebo. The lowest observed respiratory rate in study subjects in both groups was 14 breaths per minute. This respiratory rate is well above the 10 breaths per minute, which qualified as respiratory depression for this study. Additionally, no significant differences in pulse oximetry readings were observed in subjects receiving placebo versus those receiving IV difelikefalin. This study utilized supratherapeutic\u00a0IV doses of 1.0 and 5.0 mcg per kg. [10] The following adverse effects were reported in 20% to 60% of participants: Paresthesia Hypoesthesia Somnolence When study subjects experienced these adverse effects, the persistence of the symptoms ranged from less than\u00a01 minute to less than\u00a090 minutes and did not require any intervention. [10]", "contents": "Difelikefalin -- Adverse Effects. A double-blind, randomized study assessed the potential of difelikefalin to cause respiratory depression in healthy patients compared to a placebo. The lowest observed respiratory rate in study subjects in both groups was 14 breaths per minute. This respiratory rate is well above the 10 breaths per minute, which qualified as respiratory depression for this study. Additionally, no significant differences in pulse oximetry readings were observed in subjects receiving placebo versus those receiving IV difelikefalin. This study utilized supratherapeutic\u00a0IV doses of 1.0 and 5.0 mcg per kg. [10] The following adverse effects were reported in 20% to 60% of participants: Paresthesia Hypoesthesia Somnolence When study subjects experienced these adverse effects, the persistence of the symptoms ranged from less than\u00a01 minute to less than\u00a090 minutes and did not require any intervention. [10]"}
{"id": "article-132588_16", "title": "Difelikefalin -- Contraindications", "content": "No published contraindications exist for difelikefalin. Phase\u00a03 clinical trials involved patients with comorbidities and polypharmacy, demonstrating promise for difelikefalin to have generalized applicability with low risk for drug-drug interactions. Difelikefalin does not interfere with liver enzymes. [11] Of note, clinical trials have only included adult patients.\u00a0Difelikefalin should not be administered to children or adolescents.", "contents": "Difelikefalin -- Contraindications. No published contraindications exist for difelikefalin. Phase\u00a03 clinical trials involved patients with comorbidities and polypharmacy, demonstrating promise for difelikefalin to have generalized applicability with low risk for drug-drug interactions. Difelikefalin does not interfere with liver enzymes. [11] Of note, clinical trials have only included adult patients.\u00a0Difelikefalin should not be administered to children or adolescents."}
{"id": "article-132588_17", "title": "Difelikefalin -- Contraindications -- Risk of driving and operating machinery", "content": "Patients who take difelikefalin may experience dizziness, somnolence, and mental status changes.\u00a0The possibility exists\u00a0that difelikefalin may impair the physical or mental abilities needed to perform potentially hazardous activities such as driving a car and operating machinery. Therefore, patients are advised not to drive or operate dangerous machinery until the effect of\u00a0difelikefalin on their ability to drive or operate machinery is known.", "contents": "Difelikefalin -- Contraindications -- Risk of driving and operating machinery. Patients who take difelikefalin may experience dizziness, somnolence, and mental status changes.\u00a0The possibility exists\u00a0that difelikefalin may impair the physical or mental abilities needed to perform potentially hazardous activities such as driving a car and operating machinery. Therefore, patients are advised not to drive or operate dangerous machinery until the effect of\u00a0difelikefalin on their ability to drive or operate machinery is known."}
{"id": "article-132588_18", "title": "Difelikefalin -- Contraindications -- Dizziness, somnolence, mental status changes, and gait disturbances", "content": "Patients who take difelikefalin may experience mental status changes, dizziness, somnolence, and gait disturbances, including falls. However, these adverse reactions may subside over time with continued treatment. In clinical trials, more patients who received difelikefalin reported at least\u00a01 of these adverse reactions compared to those who received a placebo. The incidence of somnolence was higher in patients aged 65 years and older\u00a0than those younger. Patients should use caution when taking difelikefalin with centrally-acting depressant medications, sedating antihistamines, and opioid analgesics.", "contents": "Difelikefalin -- Contraindications -- Dizziness, somnolence, mental status changes, and gait disturbances. Patients who take difelikefalin may experience mental status changes, dizziness, somnolence, and gait disturbances, including falls. However, these adverse reactions may subside over time with continued treatment. In clinical trials, more patients who received difelikefalin reported at least\u00a01 of these adverse reactions compared to those who received a placebo. The incidence of somnolence was higher in patients aged 65 years and older\u00a0than those younger. Patients should use caution when taking difelikefalin with centrally-acting depressant medications, sedating antihistamines, and opioid analgesics."}
{"id": "article-132588_19", "title": "Difelikefalin -- Monitoring", "content": "Supportive treatment for the more commonly experienced adverse effects of difelikefalin, including vomiting and diarrhea, will increase positive patient outcomes. The health care team must avoid dehydration, acid-base disturbances, or an electrolyte imbalance when managing patients receiving difelikefalin.\u00a0Clinicians should ensure adequate hydration status and assess patients with routine labs, administering electrolyte repletion as indicated. [1] If the adverse effect of dizziness is experienced in patients taking difelikefalin, fall risk measures must be taken to avoid injury, especially in older or frail patients. Opioid withdrawal symptoms were not observed after the cessation of treatment with difelikefalin. [11]", "contents": "Difelikefalin -- Monitoring. Supportive treatment for the more commonly experienced adverse effects of difelikefalin, including vomiting and diarrhea, will increase positive patient outcomes. The health care team must avoid dehydration, acid-base disturbances, or an electrolyte imbalance when managing patients receiving difelikefalin.\u00a0Clinicians should ensure adequate hydration status and assess patients with routine labs, administering electrolyte repletion as indicated. [1] If the adverse effect of dizziness is experienced in patients taking difelikefalin, fall risk measures must be taken to avoid injury, especially in older or frail patients. Opioid withdrawal symptoms were not observed after the cessation of treatment with difelikefalin. [11]"}
{"id": "article-132588_20", "title": "Difelikefalin -- Toxicity", "content": "At supratherapeutic levels (15 mcg per mL), concern for respiratory depression or euphoric effects has not been demonstrated. [1] [10] Difelikefalin has been studied in rats and determined to cause diuresis by activating central kappa opioid receptors. [17] Mild to moderate hypernatremia has been reported at supratherapeutic doses of 1.0, 2.0, and 5.0 mcg per kg. Any induced electrolyte imbalance observed during treatment should be managed per the standard of care in conjunction with the termination of medication administration and identification of any additional etiologies for the electrolyte disturbance.\u00a0 The adverse effects mentioned previously, including hypoesthesia, paresthesia, and somnolence, are self-limiting at supratherapeutic doses. [10]", "contents": "Difelikefalin -- Toxicity. At supratherapeutic levels (15 mcg per mL), concern for respiratory depression or euphoric effects has not been demonstrated. [1] [10] Difelikefalin has been studied in rats and determined to cause diuresis by activating central kappa opioid receptors. [17] Mild to moderate hypernatremia has been reported at supratherapeutic doses of 1.0, 2.0, and 5.0 mcg per kg. Any induced electrolyte imbalance observed during treatment should be managed per the standard of care in conjunction with the termination of medication administration and identification of any additional etiologies for the electrolyte disturbance.\u00a0 The adverse effects mentioned previously, including hypoesthesia, paresthesia, and somnolence, are self-limiting at supratherapeutic doses. [10]"}
{"id": "article-132588_21", "title": "Difelikefalin -- Toxicity", "content": "No documented antidote for difelikefalin is currently in use. Considering the reassuring safety profile, the lack of activity in the CNS, and the more common adverse effects of difelikefalin subsiding without intervention, the clinical utility of naloxone in suspected supratherapeutic or toxic levels of difelikefalin is unlikely to be relevant. Phase\u00a03 double-blind, randomized, placebo-controlled clinical trials have been conducted to study the use of difelikefalin for up to 8\u00a0and 12 weeks. The potential long-term effects of difelikefalin\u00a0remain unclear.", "contents": "Difelikefalin -- Toxicity. No documented antidote for difelikefalin is currently in use. Considering the reassuring safety profile, the lack of activity in the CNS, and the more common adverse effects of difelikefalin subsiding without intervention, the clinical utility of naloxone in suspected supratherapeutic or toxic levels of difelikefalin is unlikely to be relevant. Phase\u00a03 double-blind, randomized, placebo-controlled clinical trials have been conducted to study the use of difelikefalin for up to 8\u00a0and 12 weeks. The potential long-term effects of difelikefalin\u00a0remain unclear."}
{"id": "article-132588_22", "title": "Difelikefalin -- Enhancing Healthcare Team Outcomes", "content": "The utility of a selective peripheral kappa opioid receptor agonist in treating uremic pruritis is emerging. [11] Patients with end-stage renal disease requiring dialysis face many challenges in preserving their quality of life. A coordinated effort by the nephrologist, dialysis nursing staff, patient family members, and primary care\u00a0clinicians is necessary to address the uremic pruritis often experienced by these patients appropriately so that the negative impact on the patient is diminished. [18] Common practice can evolve from current therapy for uremic pruritis, which often\u00a0ineffectively utilizes antihistamines or involves off-label use of gabapentin. [19] [20] [21]", "contents": "Difelikefalin -- Enhancing Healthcare Team Outcomes. The utility of a selective peripheral kappa opioid receptor agonist in treating uremic pruritis is emerging. [11] Patients with end-stage renal disease requiring dialysis face many challenges in preserving their quality of life. A coordinated effort by the nephrologist, dialysis nursing staff, patient family members, and primary care\u00a0clinicians is necessary to address the uremic pruritis often experienced by these patients appropriately so that the negative impact on the patient is diminished. [18] Common practice can evolve from current therapy for uremic pruritis, which often\u00a0ineffectively utilizes antihistamines or involves off-label use of gabapentin. [19] [20] [21]"}
{"id": "article-132588_23", "title": "Difelikefalin -- Enhancing Healthcare Team Outcomes", "content": "Understanding the mechanism of difelikefalin and how it effectively addresses the nonhistaminergic pathway that causes uremic pruritus is essential for the healthcare team to ensure that itching and the associated emotional distress often experienced by patients requiring dialysis may appropriately be addressed. [19] [5] The\u00a0IV dosing of difelikefalin, typically 3 times a week in\u00a0IV bolus form\u00a0after\u00a0completing dialysis sessions, is logistically ideal, enhancing team performance and subsequent patient outcomes when rendering this treatment. [4] Further research clarifying the efficacy of difelikefalin in diabetes and end-stage renal disease patients would provide valuable insight for clinical decision-making as these conditions often co-exist. [22] [21]", "contents": "Difelikefalin -- Enhancing Healthcare Team Outcomes. Understanding the mechanism of difelikefalin and how it effectively addresses the nonhistaminergic pathway that causes uremic pruritus is essential for the healthcare team to ensure that itching and the associated emotional distress often experienced by patients requiring dialysis may appropriately be addressed. [19] [5] The\u00a0IV dosing of difelikefalin, typically 3 times a week in\u00a0IV bolus form\u00a0after\u00a0completing dialysis sessions, is logistically ideal, enhancing team performance and subsequent patient outcomes when rendering this treatment. [4] Further research clarifying the efficacy of difelikefalin in diabetes and end-stage renal disease patients would provide valuable insight for clinical decision-making as these conditions often co-exist. [22] [21]"}
{"id": "article-132588_24", "title": "Difelikefalin -- Enhancing Healthcare Team Outcomes", "content": "The opioid crisis facing the healthcare industry today\u00a0requires\u00a0the introduction of safer\u00a0postoperative pain medications with decreased abuse potential. Surgeons and primary care clinicians can initiate\u00a0IV or oral difelikefalin for patients with acute postoperative pain or sub-acute and chronic pain, without\u00a0significant concerns for lethal overdose or euphoric effects, even at supratherapeutic doses. [1] The extensive development of safer formulations of traditional oral opioid medications\u00a0for pain management without the risk of misuse potential demonstrates\u00a0a need that the novel difelikefalin oral formulation would fulfill\u00a0through widespread implementation by healthcare providers. [21] [1] [14] Trials are currently underway to test\u00a0difelikefalin for use in controlling postoperative pain; early results have shown promise regarding cost-effectiveness, clinical efficacy, and adverse event profile, but more research is necessary. [2]", "contents": "Difelikefalin -- Enhancing Healthcare Team Outcomes. The opioid crisis facing the healthcare industry today\u00a0requires\u00a0the introduction of safer\u00a0postoperative pain medications with decreased abuse potential. Surgeons and primary care clinicians can initiate\u00a0IV or oral difelikefalin for patients with acute postoperative pain or sub-acute and chronic pain, without\u00a0significant concerns for lethal overdose or euphoric effects, even at supratherapeutic doses. [1] The extensive development of safer formulations of traditional oral opioid medications\u00a0for pain management without the risk of misuse potential demonstrates\u00a0a need that the novel difelikefalin oral formulation would fulfill\u00a0through widespread implementation by healthcare providers. [21] [1] [14] Trials are currently underway to test\u00a0difelikefalin for use in controlling postoperative pain; early results have shown promise regarding cost-effectiveness, clinical efficacy, and adverse event profile, but more research is necessary. [2]"}
{"id": "article-132588_25", "title": "Difelikefalin -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Difelikefalin -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}